MedPath

Implementation of Pharmacogenetic Testing in Hospital Wards

Not Applicable
Completed
Conditions
Admitted Multimorbid Patients
Interventions
Genetic: Pharmacogenetic test
Other: Medication review
Registration Number
NCT04573491
Lead Sponsor
Hospital Pharmacy Enterprise, South Eastern Norway
Brief Summary

The purpose of this study is to investigate whether it is feasible to implement pharmacogenetic testing as part of medication review while the patient is admitted to hospital.

Detailed Description

Earlier studies have shown that pharmacogenetic testing may contribute to optimizing the efficacy of medication treatment and to reduce the risk of adverse effects. Inclusion of pharmacogenetic testing as part of medication reviews reveals more serious drug related problems and leads to more changes in medication treatment than medication review alone.

The use of pharmacogenetic testing as part of medication reviews has not earlier been systematically investigated in hospital patients in Norway. There is little documentation of what is needed to implement the use of pharmacogenetic testing in a hospital ward.

The investigators are conducting a descriptive study in two internal medicine wards at Akershus University Hospital. 50 patients using minimum 5 regular drugs including at least one relevant for pharmacogenetic testing will be enrolled in the study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
46
Inclusion Criteria
  • at least 2 long-term conditions
  • at least 5 regular drugs of which at least one relevant for pharmacogenetic testing
  • at least 2 years life expectancy
  • able to communicate in Norwegian
  • able to give informed consent
  • summary care record
Exclusion Criteria
  • moderate to severe dementia

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Pharmacogenetic testPharmacogenetic testMedication review including results from pharmacogenetic testing
Pharmacogenetic testMedication reviewMedication review including results from pharmacogenetic testing
Primary Outcome Measures
NameTimeMethod
Number of patients with results from pharmacogenetic testing included in medication reviewfrom admission to discharge, an average of 1 week

Number of patients

Secondary Outcome Measures
NameTimeMethod
Acceptance of recommendationsafter medication review and before discharge, an average of 3 days

Degree of acceptance of recommendations after pharmacogenetic testing, by prescribers

Documentation of information from pharmacogenetic testingafter medication review and before discharge, an average of 3 days

Number of patients with information from pharmacogenetic testing documented in the patient journal

Trial Locations

Locations (1)

Akershus University Hospital

🇳🇴

Lørenskog, Nordbyhagen, Norway

© Copyright 2025. All Rights Reserved by MedPath